✦ LIBER ✦

An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting

✍ Scribed by I.T. Jantunen; V.V. Kataja; T.T. Muhonen

Book ID: 117663552
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 933 KB
Volume: 33
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(96)00276-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dexamethasone can potentiate the anti-em

Dexamethasone can potentiate the anti-emetic action of a 5HT3 receptor antagonist on cyclophosphamide induced vomiting in the ferret

✍ Hawthorn, J; Cunningham, D 📂 Article 📅 1990 🏛 Nature Publishing Group 🌐 English ⚖ 877 KB

GR38032F, a 5HT3receptor antagonist, in

GR38032F, a 5HT3receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting

✍ Michel Marty; Jean P. Droz; Pierre Pouillart; Bernard Paule; Nils Brion; Jacques 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 330 KB

A total of 28 patients receiving cancer chemotherapy with cisplatin-containing regimens (70-120 mg/ m 2) participated in an evaluation of the efficacy and safety of GR38032F for the prevention of acute nausea and vomiting. GR38032F, a 5HT3 receptor antagonist, was given 30 min prior to cisplatin as

A phase I/II study of the 5-HT3 antagoni

A phase I/II study of the 5-HT3 antagonist GR38032F in the anti-emetic prophylaxis of patients receiving high-dose cisplatin chemotherapy

✍ D. B. Smith; E. S. Newlands; G. J. S. Rustin; R. H. J. Begent; S. M. Crawford; K 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 379 KB

A phase I study of a new 5HT3-receptor a

A phase I study of a new 5HT3-receptor antagonist, BRL43694A, an agent for the prevention of chemotherapy-induced nausea and vomiting

✍ Geoffrey Falkson; Adriaan J. Zyl 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 370 KB

In a phase I study of BRL43694A, a 5HT3-receptor antagonist, a single dose of 40 micrograms/kg was given to 24 patients. All patients received cytostatic treatment expected to cause nausea and vomiting. During the first 24 h, 12 patients were completely protected from nausea and vomiting, 4 experien